Fuyuhiko Tamanoi - Genetic Mutations

Author Information

Fuyuhiko Tamanoi is affiliated with the Institute for Integrated Cell-Material Sciences and the Institute for Advanced Study at Kyoto University in Kyoto, Japan. He also holds a position in the Department of Microbiology, Immunology & Molecular Genetics at the University of California, Los Angeles (UCLA), in Los Angeles, CA, United States.

Research Contributions

Fuyuhiko Tamanoi's research primarily focuses on the development and application of nanoparticle-based technologies for cancer therapy. His work includes the synthesis and evaluation of biodegradable mesoporous nanoparticles, the use of magnetic nanoparticles in conjunction with alternating magnetic fields, and the investigation of tumor models such as the chick chorioallantoic membrane (CAM) model for precision medicine. His recent studies have explored the use of periodic mesoporous organosilica (BPMO) nanomaterials and iodine-containing nanoparticles for enhancing anti-cancer efficacy and overcoming biological barriers.

Aliases

Fuyuhiko Tamanoi is also known by several other names, including F Tamanoi, F. Tamanoi, and Fuyu Tamanoi.

Publication and Citation Metrics

Metric	Value
Total Citation Count	16,477
h-index	68
Total Papers Published	269

Publications:

Tumor Accumulation of PIP-Based KRAS Inhibitor KR12 Evaluated by the Use of a Simple, Versatile Chicken Egg Tumor Model

DOI: 10.3390/cancers14040951

Year: 2022

Magnetic Nanoparticles and Alternating Magnetic Field for Cancer Therapy

DOI: 10.1007/978-3-030-55924-3_7

Year: 2021

Facile synthesis of biodegradable mesoporous functionalized-organosilica nanoparticles for enhancing the anti-cancer efficiency of cordycepin

DOI: 10.1016/J.MICROMESO.2021.110913

Year: 2021

Construction of Boronophenylalanine-Loaded Biodegradable Periodic Mesoporous Organosilica Nanoparticles for BNCT Cancer Therapy

DOI: 10.3390/ijms22052251

Year: 2021

The CAM Model for CIC-DUX4 Sarcoma and Its Potential Use for Precision Medicine

DOI: 10.3390/cells10102613

Year: 2021

Correction to: Magnetic Nanoparticles and Alternating Magnetic Field for Cancer Therapy

DOI: 10.1007/978-3-030-55924-3_12

Year: 2021

Iodine containing porous organosilica nanoparticles trigger tumor spheroids destruction upon monochromatic X-ray irradiation: DNA breaks and K-edge energy X-ray

DOI: 10.1038/s41598-021-93429-9

Year: 2021

Designing Mesoporous Silica Nanoparticles to Overcome Biological Barriers by Incorporating Targeting and Endosomal Escape

DOI: 10.1021/acsami.0c21507

Year: 2021

Abstract 1670: Characterization of the chick chorioallantoic membrane tumor model in comparison with various xenograft mouse tumors

DOI: 10.1158/1538-7445.am2020-1670

Year: 2020

Recent Development to Explore the Use of Biodegradable Periodic Mesoporous Organosilica (BPMO) Nanomaterials for Cancer Therapy

DOI: 10.3390/pharmaceutics12090890

Year: 2020

What is the Mechanism of Action of TKIs?

What Types of Data are Analyzed?

What Types of Chemicals Are Known Mutagens?

What are Neutral Mutations?

How do ZFNs compare to other genome editing tools?

What is Genetic Coding?

How do Genetic Mutations Lead to Cancer?

What Types of Mutations Occur in Non-Coding Regions?

What is the Delta F508 Mutation?

What Are the Consequences of Transversions?

Partnered Content Networks

Relevant Topics